Detail akcie MultiCell Techn online

Business Summary: MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Financial Summary: BRIEF: For the nine months ended 31 August 2015, Multicell Technologies Inc revenues increased from $37K to $793K. Net loss decreased 34% to $250K. Revenues reflect License revenue increase from $37K to $537K. Lower net loss reflects Research and development decrease of 35% to $184K (expense), Change in fair value of derivative liab. increase from $15K (expense) to $9K (income), Interest expense decrease of 81% to $2K (expense).